Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies

作者：Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Zaid Al‐Kadhimi, Manuel Espinoza‐Gutarra, Ravi Bhatia, Omer Jamy · 发表于：eJHaem · 年份：2024 · DOI：10.1002/jha2.915 · 被引用次数：6 · 研究领域：Acute Myeloid Leukemia Research、Chronic Myeloid Leukemia Treatments、Hematopoietic Stem Cell Transplantation

Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low-dose decitabine and venetoclax (DEC/VEN) as post-transplant maintenance in 26 older patients with AML and MDS. The cumulative incidence of day 100 gIII-IV acute graft versus host disease (GVHD) and 1-year moderate-severe chronic GVHD was 5% and 26%, respectively. One patient relapsed 14 m after transplant. The 1-year non-relapse mortality and survival were 11% and 84%, respectively. DEC/VEN is a safe and potentially effective strategy to reduce the risk of post-transplant relapse.